PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Cerevel Therapeutics Holdings, Inc. (CERE)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US15678U1280

CUSIP

15678U128

Sector

Healthcare

IPO Date

Oct 28, 2020

Highlights

Market Cap

$8.19B

EPS (TTM)

-$2.73

Total Revenue (TTM)

$8.25M

Gross Profit (TTM)

-$1.54M

EBITDA (TTM)

-$127.58M

Year Range

$38.50 - $44.99

Target Price

$43.40

Short %

6.88%

Short Ratio

2.37

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Cerevel Therapeutics Holdings, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


CERE (Cerevel Therapeutics Holdings, Inc.)
Benchmark (^GSPC)

Returns By Period


CERE

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

3.96%

1M

1.97%

6M

9.03%

1Y

22.16%

5Y*

12.60%

10Y*

11.26%

*Annualized

Monthly Returns

The table below presents the monthly returns of CERE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-1.18%-2.15%3.10%1.04%-4.61%0.37%9.95%6.04%
20238.28%-21.84%-8.62%19.07%12.26%-2.48%-3.77%-22.52%-7.89%8.34%9.64%63.52%34.43%
2022-19.68%1.65%32.26%-16.37%-10.76%1.19%-0.57%10.69%-2.89%-1.06%3.58%8.91%-2.71%
2021-22.38%17.79%-9.43%5.97%-9.83%95.27%-3.83%28.49%-6.82%37.80%-23.27%3.94%95.54%
20204.25%37.09%17.42%67.81%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 97, CERE is among the top 3% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of CERE is 9797
Overall Rank
The Sharpe Ratio Rank of CERE is 9898
Sharpe Ratio Rank
The Sortino Ratio Rank of CERE is 9999
Sortino Ratio Rank
The Omega Ratio Rank of CERE is 9898
Omega Ratio Rank
The Calmar Ratio Rank of CERE is 9292
Calmar Ratio Rank
The Martin Ratio Rank of CERE is 9999
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Cerevel Therapeutics Holdings, Inc. (CERE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
No data
CERE
^GSPC

There is not enough data available to calculate the Sharpe ratio for Cerevel Therapeutics Holdings, Inc.. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio
CERE (Cerevel Therapeutics Holdings, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Cerevel Therapeutics Holdings, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


CERE (Cerevel Therapeutics Holdings, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Cerevel Therapeutics Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Cerevel Therapeutics Holdings, Inc. was 54.61%, occurring on Sep 22, 2023. Recovery took 214 trading sessions.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-54.61%Nov 5, 2021472Sep 22, 2023214Jul 31, 2024686
-32.29%Dec 18, 202069Mar 30, 202163Jun 29, 2021132
-28.39%Jun 30, 202112Jul 16, 202129Aug 26, 202141
-24.07%Sep 22, 20217Sep 30, 202116Oct 22, 202123
-6.57%Dec 8, 20201Dec 8, 20207Dec 17, 20208

Volatility

Volatility Chart

The current Cerevel Therapeutics Holdings, Inc. volatility is 5.12%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


CERE (Cerevel Therapeutics Holdings, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Cerevel Therapeutics Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Cerevel Therapeutics Holdings, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab